Flexible approach to the appointment of solifenacin: for whom and when?
- Authors: Kasyan G.R1
-
Affiliations:
- Issue: No 5 (2013)
- Pages: 92-95
- Section: Articles
- URL: https://journals.eco-vector.com/1728-2985/article/view/279978
- ID: 279978
Cite item
Open Access
Access granted
Abstract
Solifenacin at a dose of 5 mg per day has demonstrated the high efficacy in the treatment of patients with overactive bladder. However, for patients who remained dissatisfied with the outcome of treatment, the dose may be increased to 10 mg per day, which leads to the improvement of patient's condition. However, there is an opinion that treatment should be started with the use of high doses of the drug. Efficiency of solifenacin at a dose of 10 mg was accompanied by favorable safety and tolerability profile. Despite the fact that numerous studies have shown that the clinical efficacy of different anticholinergics is not very different from one another, it is known that patients may prefer some other drugs. Application of solifenacin in these patients leads to significant improvement in quality of life. Thus, flexible approach to the use of solifenacin allows to achieve the best results in the treatment of patients, including those cases where the initial treatment is not effective or is interrupted due to pronounced side effects.
Full Text
References
- Milsom I., Abrams P., Cardozo L. et al. How widespread are the symptoms of overactive bladder and how are they managed? A population-based prevalence study. BJU Int. 2001 ;87(9):760-766.
- Nabi G., Cody J.D., Ellis G. et al. Anticholinergic drugs versus placebo for overactive bladder syndrome in adults. Cochrane Database Syst. Rev. 2006;4 CD003781.
- Abrams P., Swift S. Solifenacin is effective for the treatment of OAB dry patients: a pooled analysis. Eur. Urol. 2005;48(3):483-487.
- Chapple C.R., Martinez-Garcia R., Selvaggi L. et al. A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial. Eur. Urol. 2005;48(3):464-470.
- Cardozo L., Heßdörfer E., Milani R. et al. Solifenacin in the treatment of urgency and other symptoms of overactive bladder: results from a randomized, double-blind, placebo-controlled, rising-dose trial. Br. J Urol. Int. 2008;102(9):1120-1127.
- Sears C.L.G., Lewis C., Noel K. et al. Overactive bladder medication adherence when medication is free to patients. J Urol. 2010;183(3):1077-1081.
- D'Souza A.O., Smith M.J., Miller L.A. et al. Persistence, adherence, and switch rates among extended-release and immediate-release overactive bladder medications in a regional managed care plan. J Managed Care Pharmacy. 2008;14(3):291-301.
- Haab F., Castro-Diaz D. Persistence with antimuscarinic therapy in patients with overactive bladder. Int J Clin Pract. 2005; 59(8):931-937.
- Chapple C.R., Rosenberg M.T., Brenes F.J. Listening to the patient: a flexible approach to the use of antimuscarinic agents in overactive bladder syndrome. Br J Urol Int. 2009; 104(7): 960-967.
- Wyndaele J.-J., Goldfischer E.R., Morrow J.D. et al. Effects of flexible-dose fesoterodine on overactive bladder symptoms and treatment satisfaction: an open-label study. Int J Clin Pract. 2009;63(4):560-567.
- Chu F., Smith N., Uchida T. Efficacy and Safety of Solifenacin Succinate 10 mg Once Daily: A Multicenter, Phase III, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Trial in Patients With Overactive Bladder. Curr Ther Res Clin Exp. 2009; 70: 405-420.
- Chancellor M.B., Zinner N., Whitmore K. et al. Efficacy of solifenacin in patients previously treated with tolterodine extended release 4 mg: results of a 12-week, multicenter, open-label, flexible-dose study. Clinical Therapeutics. 2008;30(10): 1766-1781.
- Zinner N., Kobashi K. C., Ebinger U. et al. Darifenacin treatment for overactive bladder in patients who expressed dissatisfaction with prior extended-release antimuscarinic therapy. Int J Clin Pract. 2008;62(11):1664—1674.
- Wyndaele J.-J., Goldfischer E.R., Morrow J.D. et al. Patientoptimized doses of fesoterodine improve bladder symptoms in an open-label, flexible-dose study. Br J Urol. Int.2011; 107(4):603-611.
- Karram M.M., Toglia M.R., Serels S.R. et al. Treatment with solifenacin increases warning time and improves symptoms of overactive bladder; results from VENUS, a randomised double blind placebo-controlled trial. Urology 2009;73:14-18.
- Garley A.D., Kaufman J.M., Sand P.K. et al. Symptom bother and healthrelated quality of life outcomes following solifenacin treatment for overactive bladder: the Vesicare open label trial. Clin. Ther. 2006;28:1935-1946.
- Michel M.C., Wetterauer U., Vogel M. et al. Cardiovascular safety and overall tolerability of solifenacin in routine clinical use: a 12 week open label postmarketing surveillance study. Drug Saf. 2008;31:505-514.
Supplementary files
